All News

Article

Worldwide Trends in Hyperuricemia

Jack Cush, MD

A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates

Article

B cell Targeted CAR-T Therapy for Autoimmune Diseases

EurekAlert!

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with unprecedented specificity.

Dr. John Cush Tweet
RheumNow
The Role of Calcineurin Inhibitors in Lupus Nephritis In the U.S, lupus nephritis affects approximately 40–50% of patients with systemic lupus erythematosus (SLE), contributing significantly to the morbidity and mortality of the affected individuals (1). However, significant https://t.co/sc4cgAYzGy
Dr. John Cush Tweet
RheumNow
TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active PsA based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. https://t.co/a6rmortnoS
Dr. John Cush Tweet
RheumNow
Update on FDA complete response letter to AZ regarding BLA hold for anifrolumab (Saphnelo) for SC use in SLE. CRL originally issued 10/10/25, but announced 2/3/26. FDA CRL cites critical data quality w/ key analyses in SC-TULIP study. A BLA decision expected in 1st half of 2026 https://t.co/zuwtsdL6I9
Dr. John Cush Tweet
RheumNow
FDA has approved deucravacitinib (Sotyktu) the Treatment of Adults with Active Psoriatic Arthritis based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. Sotyktu is the only tyrosine kinase 2 (TYK2) inhibitor to be approved for PsA https://t.co/8xBrgPfENH
Dr. John Cush Tweet
RheumNow
Open-label experience with upadacitinib in 27 Behcets pts (median 36 yrs) w/ median BDCAF 4 (2–7). At 6 mos overall response seen in 23/27 (85%) (16 CRs, 7 PRs) w/ signif reductions in BDCAF, CRP, ESR, & steroid dose by week 24. 3 pts relapsed during F/U https://t.co/VXkskVyWgT
Dr. John Cush Tweet
RheumNow
Progress in GCA and Takayasu's Arteritis Despite carefully planned taper schedules, about 75% of GCA patients remain on glucocorticoids after 4 years, and 74% experience side effects. In rheumatology, prolonged steroid use often leads to expected toxicity. https://t.co/l65ER5rGU8
×